SAINT GOBAIN 85.440 € (+0,85 %)
AMUNDI 96.750 € (-0,36 %)
SANOFI 75.310 € (+1,35 %)
COFACE 16.100 € (-0,19 %)
TOMTOM 4.042 € (+1,56 %)
X-FAB 7.030 € (+3,84 %)
MAROC TELECOM 9.000 € (+0,22 %)
UMG 15.565 € (+2,71 %)
SOITEC 122.500 € (+1,45 %)
PHILIPS KON 23.130 € (+0,70 %)
UNILEVER 54.650 € (-0,78 %)
ATOS GROUP 31.700 € (-0,13 %)
CARVOLIX 6.200 € (-1,90 %)
ENERGY SOLAR 1.400 € (+1,08 %)
MEDINCELL 24.500 € (-1,69 %)
AALBERTS NV 45.080 € (+0,54 %)
L'OREAL 385.900 € (-1,15 %)
S.E.B. 59.500 € (-0,67 %)
BONDUELLE 8.610 € (-1,37 %)
LUMIBIRD 27.000 € (+1,50 %)
ADYEN 930.300 € (-0,31 %)
PEUGEOT INVEST 57.500 € (+0,35 %)
LAKEFRONT BIOTHER. 23.340 € (+3,83 %)
LVMH 480.000 € (-0,30 %)
ENGIE 26.720 € (+0,60 %)
CSG 17.714 € (-8,02 %)
ABN AMRO BANK N.V. 39.730 € (-0,13 %)
SBM OFFSHORE 32.400 € (-7,69 %)
BUREAU VERITAS 28.360 € (-0,28 %)
AB SCIENCE 1.000 € (+24,07 %)
KERING 286.650 € (-1,07 %)
BOUYGUES 48.640 € (-1,12 %)
AKZO NOBEL 63.520 € (-0,06 %)
NANOBIOTIX 33.460 € (+0,78 %)
HEINEKEN 77.140 € (-0,87 %)
ALTAREA 100.400 € (-0,20 %)
RUBIS 33.400 € (+0,30 %)
REMY COINTREAU 46.600 € (+2,69 %)
KAUFMAN ET BROAD 25.250 € (+0,60 %)
TELEPERFORMANCE 70.000 € (+1,92 %)
HAFFNER ENERGY 0.456 € (-1,19 %)
SHELL PLC 38.390 € (-1,01 %)
2CRSI 27.600 € (-0,79 %)
LISI 67.200 € (+1,66 %)
TRIGANO 152.900 € (+1,12 %)
V LANSCHOT KEMPEN 65.250 € (-0,76 %)
TIKEHAU CAPITAL 17.020 € (+0,59 %)
HEINEKEN HOLDING 72.650 € (-1,29 %)
Coca-ColaEuropacif 92.900 € (-1,06 %)
UNIFY GROUP 1.862 € (-0,53 %)
POSTNL 0.911 € (-2,57 %)
ASML HOLDING 1 499.000 € (+0,33 %)
PHARMING GROUP 0.960 € (+1,52 %)
EXAIL TECHNOLOGIES 124.600 € (+0,08 %)
VETOQUINOL 72.600 € (+1,82 %)
CTP 14.680 € (-3,17 %)
TOTALENERGIES 74.090 € (-0,60 %)
CROSSJECT 1.498 € (-1,45 %)
RELX 30.840 € (+1,05 %)
VEOLIA ENVIRON. 35.190 € (+0,34 %) |
27/06/2026 00:05
EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing lossEQS-News: EAN Congress / Key word(s): Miscellaneous GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to new research presented at the European Academy of Neurology (EAN) Congress 2026. Hearing loss is widely recognised as the largest modifiable risk factor for dementia. Yet whether hearing aids can reduce dementia risk remains debated. To explore this, researchers from University Hospital Zurich and the University of Liverpool analysed electronic health records from more than 250 million patients in the TriNetX network. They compared adults with hearing loss who used hearing aids with closely matched adults who did not. The analysis included the overall hearing-loss population as well as people living with epilepsy, stroke, type 2 diabetes, chronic kidney disease, heart failure, migraine and osteoarthritis. No significant association was found between hearing aid use and dementia risk in the overall population with hearing loss, nor among people with stroke, migraine, type 2 diabetes, chronic kidney disease, heart failure or osteoarthritis. However, among adults with both epilepsy and hearing loss, hearing aid use was associated with a 23% lower risk of dementia. This corresponded to an absolute risk reduction of 2.7 percentage points over five years, equivalent to one fewer case of dementia for every 37 people using hearing aids. The researchers believe the findings may be explained by differences in cognitive reserve – the brain's ability to continue functioning effectively despite age-related changes or damage caused by disease. Lead author Dr Carolina Ferreira-Atuesta explained: "Most people with hearing loss have enough cognitive reserve to absorb the extra effort caused by hearing impairment, so correcting it may not have a large effect on dementia risk. Epilepsy is different because cognitive reserve is often already reduced, meaning that removing one additional source of strain may have a greater impact." "There are several biologically plausible reasons why we might see this effect in epilepsy. The condition is associated with accelerated cognitive decline, temporal lobe epilepsy affects areas of the brain involved in hearing and some anti-seizure medications may worsen hearing," added Dr Ferreira-Atuesta. The findings have important implications for clinical practice, according to the researchers. Since people with epilepsy are already in regular contact with healthcare services, hearing assessments could be readily incorporated into routine care.
![]() 27.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2355238 27.06.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
